Skip to main content
. 2022 Jun 26;17(6):1739–1749. doi: 10.1007/s11739-022-03000-1

Fig. 1.

Fig. 1

Prevalence of SARS-CoV-2 infection in patients with metabolic comorbidities stratified by liver disease. Bars represent prevalence of severe SARS-CoV-2 infection in patients with obesity, hypertension, type 2 diabetes (T2DM), and dyslipidaemia with (black) or without (grey) baseline transaminases > 2ULN (A), with (black) or without (grey) hepatic steatosis (B), with (grey) FIB-4 < 1.45 or ≥ 1.45 (black) (C)